Immnuocellular Therapeutics | IMUC | Profile | Summary

 ImmunoCellular Therapeutics is developing immune-based therapies for the treatment of brain cancer and other tumors. Our lead product candidate, ICT-107, is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma multiforme (GBM), the most common and lethal type of brain cancer. Our pipeline also includes ICT-121, a dendritic cell (DC) vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells.

ImmunoCellular Therapeutics aims to become an industry-leading, independent, commercial-stage cancer immunotherapy company serving patients in major markets.

ImmunoCellular Cancer Vaccine Manufacturing Process

Each of ImmunoCellular’s dendritic cell (DC) vaccines is prepared from blood collected from each patient. The process, which takes only a few days to complete, is designed to generate sufficient cryopreserved (frozen) cells for dosing through the induction and maintenance phases of immunotherapy. Our GMP manufacturing process adheres strictly to standard operating procedures to ensure consistency, quality and sterility.

The process begins with an apheresis (also referred to as leukapheresis), a common procedure in which the patient’s blood is circulated through a machine to collect the white blood cells.

ImmunoCellular Therapeutics’ proprietary cancer vaccine immunotherapy technology has the potential to transform the treatment of cancer by improving survival and offering safer and more effective treatments than conventional cancer therapies. Our dendritic cell (DC)-based immunotherapies are designed to target both tumor cells as well as cancer stem cells by utilizing multiple tumor-specific antigens to trigger a powerful antitumor immune system response. Utilizing an advanced manufacturing process, we can produce multiple doses from a single apheresis, and offer the advantages of potency, versatility, efficiency, cost-effectiveness and convenience compared to earlier generation cancer vaccines.

Our dendritic cell (DC) vaccine technology and advanced manufacturing offer several advantages over earlier-generation cellular immunotherapies:

• Potency

  • Matured DCs secrete IL12, which is critical for stimulating T cell killing of cancer cells.

  • More than 80% of the final manufactured product consists of matured DCs.

• Versatility

  • Unlike other cell-based vaccines, our DCs target multiple antigens, thus increasing the likelihood of effective treatment.

• Efficiency

  • Advanced manufacturing enables production of at least 20 doses of vaccine from a single apheresis (blood collection); thus patients do not need to undergo additional apheresis procedures.

• Cost-effectiveness

  • Compared to the only approved cell-based immunotherapy, our DC vaccines can be manufactured at a significantly reduced cost.

• Convenience

  • Ability to freeze and store vaccine for months or years eliminates the need to administer to the patient shortly after manufacture.

  • Intradermal administration route reduces the time and inconvenience of intravenous infusion for both patient and physician.

Source: IMUC, OxBridge Research, Daily Stock Deal, OTCking

Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Disclaimer/Disclosure: we receive compensation from companies we feature on our websites/blogs/emails/newsletters or comment on social media/FB/TWTR etc. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.